Chapter 1  Introduction 9

Chapter 2  Reduced biological activity of recombinant IFN-β and treatment response 29
  2.1 IFN-β bioactivity measurement in MS: feasibility for routine clinical practice 31
  2.2 Lack of IFN-β bioactivity is associated with the occurrence of relapses in MS 43
  2.3 IRF5 gene variants and pharmacological and clinical outcome of IFN-β therapy in MS 53
  2.4 IL7R genotype and mRNA expression in Dutch MS patients and response to IFN-β 67

Chapter 3  Endogenous type I IFN pathways and disease activity in MS 81
  3.1 Spontaneous MxA mRNA level predicts relapses in patients with recently diagnosed MS 83
  3.2 Long-term blocking of endogenous IFN-β by persisting NAbs after IFN-β treatment discontinuation 95

Chapter 4  General discussion and Future Perspectives 107
  Abbreviations 125
  Dutch summary 129
  List of publications 137
  Dankwoord 141
  About the author 147